# BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 P&L / Income Statement

- Company: BridgeBio Pharma, Inc. (BBIO)
- Period: 2026-01-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001743881-26-000034
- Page: https://plicit.ai/financials/bbio/fy2026-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/bbio-fy2026-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 791,362,000 US dollars
- **Total cost of revenues**: 45,435,000 US dollars
- **Gross profit (calculated)**: 745,927,000 US dollars
- **Operating expenses (calculated)**: 970,601,000 US dollars
- **Loss from operations**: negative 224,674,000 US dollars
- **Total other expense, net**: negative 157,039,000 US dollars
- **Loss before income taxes**: negative 381,713,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 382,942,000 US dollars
- **Net product revenue**: 656,382,000 US dollars
- **License and services revenue**: 89,537,000 US dollars
- **Royalty revenue**: 45,443,000 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 419,590,000 US dollars
- **Selling, general and administrative**: 551,011,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$372.97 M; to noncontrolling interests: −$9.97 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/bbio/fy2026-ytd-q3-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/bbio-fy2026-ytd-q3-revenue-by-geography-sankey.png

Income statement for 2026-01-01 through 2026-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 791,362,000 US dollars
- **Total cost of revenues**: 45,435,000 US dollars
- **Gross profit (calculated)**: 745,927,000 US dollars
- **Operating expenses (calculated)**: 970,601,000 US dollars
- **Loss from operations**: negative 224,674,000 US dollars
- **Total other expense, net**: negative 157,039,000 US dollars
- **Loss before income taxes**: negative 381,713,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 382,942,000 US dollars
- **UNITED STATES (calculated)**: 656,039,098 US dollars
- **Asia Pacific (calculated)**: 6,330,896 US dollars
- **EMEA (calculated)**: 128,992,006 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 419,590,000 US dollars
- **Selling, general and administrative**: 551,011,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$372.97 M; to noncontrolling interests: −$9.97 M.

## Chart details: Revenue by Business Segment by Product and Service

- Page: https://plicit.ai/financials/bbio/fy2026-ytd-q3-income-statement/revenue-by-business-segment-by-product-and-service
- Chart image: https://plicit.ai/charts/bbio-fy2026-ytd-q3-revenue-by-business-segment-by-product-and-service-sankey.png

Income statement for 2026-01-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 791,362,000 US dollars
- **Total cost of revenues**: 45,435,000 US dollars
- **Gross profit (calculated)**: 745,927,000 US dollars
- **Operating expenses (calculated)**: 970,601,000 US dollars
- **Loss from operations**: negative 224,674,000 US dollars
- **Total other expense, net**: negative 157,039,000 US dollars
- **Loss before income taxes**: negative 381,713,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 382,942,000 US dollars
- **Reportable Segment - License and services revenue**: 89,537,000 US dollars
- **Reportable Segment - Net product revenue**: 656,382,000 US dollars
- **Reportable Segment - Royalty revenue**: 45,443,000 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 419,590,000 US dollars
- **Selling, general and administrative**: 551,011,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$372.97 M; to noncontrolling interests: −$9.97 M.
